Sectors
APGE
Apogee Therapeutics, Inc.
134.69
1 x 134.70
1 x 146.34
bid
ask
+
0.04
0.03%
25 @ 04:00 PM
134.64 -0.05 (0.03%)
| Ytd | 78.44% | |
| 1y | 288.72% |
134.58
day range
134.72
34.58
52 week range
134.88
| Open | 134.60 | Prev Close | 134.65 | Low | 134.58 | High | 134.72 | Mkt Cap | 8.33B |
| Vol | 1.05M | Avg Vol | 2.68M | EPS | -4.33 | P/E | -31.11 | Forward P/E | -25.95 |
| Beta | 0.35 | Short Ratio | 0.71 | Inst. Own | 110.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 120.28 | 200-d Avg | 85.72 | 1yr Est | 130.53 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-09 | 2026-09 | -1.14 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -1.07 | -1.14 | -0.07 | -6.54% |
| 2026-05-11 | 2026-03 | -1.07 | -1.06 | 0.01 | 0.93% |
| 2026-03-02 | 2025-12 | -1.05 | -1.03 | 0.02 | 1.90% |
| 2025-11-10 | 2025-09 | -1.12 | -1.11 | 0.01 | 0.89% |
| 2025-08-11 | 2025-06 | -1.03 | -1.13 | -0.1 | -9.71% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-24 | Stifel | Downgrade | Buy | Hold |
| 2026-06-24 | TD Cowen | Downgrade | Buy | Hold |
| 2026-06-24 | Guggenheim | Downgrade | Buy | Neutral |
| 2026-06-24 | Mizuho | Downgrade | Outperform | Neutral |
| 2026-06-23 | Deutsche Bank | Downgrade | Buy | Hold |
| 2026-06-23 | Citigroup | Downgrade | Buy | Neutral |
Profile
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-04 | DAMBKOWSKI CARL | Officer | 168.50K | Sale |
| 2026-01-21 | FAIRMOUNT FUNDS MANAGEMENT LLC | Unknown | 0.00 | Sale |
| 2026-07-23 | HENDERSON JANE | Chief Financial Officer | 158.37K | Stock Gift |
| 2026-07-09 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 920.94K | Stock Gift |
| 2024-12-11 | MCKENNA MARK C | Director | 20.00K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Investment Management, Inc. | 10.30M | 1.39B | 16.65% |
| 2026-03-30 | FMR, LLC | 9.26M | 1.25B | 14.97% |
| 2026-03-30 | Venrock Adviser, LLC | 8.49M | 1.14B | 13.73% |
| 2026-06-29 | Blackrock Inc. | 5.51M | 741.74M | 8.90% |
| 2026-03-30 | Wellington Management Group, LLP | 4.38M | 589.36M | 7.07% |
| 2026-03-30 | RTW Investments LP | 2.78M | 374.72M | 4.50% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 5.30M | 713.31M | 8.56% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.84M | 247.88M | 2.97% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.49M | 200.79M | 2.41% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.20M | 161.52M | 1.94% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.16M | 156.85M | 1.88% |
| 2026-03-30 | JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 1.13M | 151.62M | 1.82% |